MG
ABOS icon

Michael Gelband’s Acumen Pharmaceuticals ABOS Stock Holding History

Michael Gelband’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,620
Closed -$104K – 1464
2024
Q1 		$104K Sell
25,620
-6,636
-21% -$25K ﹤0.01% 1411
2023
Q4 		$124K Buy
+32,256
New +$95.7K ﹤0.01% 1337

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Michael Gelband's ABOS Position: Q2 2024 in Review

Michael Gelband sold out of Acumen Pharmaceuticals (ABOS) in Q2 2024, closing a stake of 25,620 shares — an estimated $104K sold.

Michael Gelband first reported a position in ABOS in Q4 2023 and held it in 2 quarters. The position peaked at $124K in Q4 2023. 81 funds tracked by Wall St. Rank hold ABOS as of Q2 2024.

  • Michael Gelband reported no remaining Acumen Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Michael Gelband sold 25,620 Acumen Pharmaceuticals shares in Q2 2024, an estimated $104K.
  • Michael Gelband first reported a position in Acumen Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Michael Gelband's Acumen Pharmaceuticals position peaked at $124K in Q4 2023.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.